Plain-English translation of NCT06016920 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two treatments for advanced throat cancer caused by the HPV16 virus. The new treatment is called , a therapeutic vaccine designed to train your immune system to fight cancer cells. It will be given together with , a standard immunotherapy medication that helps your body's immune system recognize and destroy cancer.
Currently, patients with advanced HPV-related throat cancer are treated with alone. Researchers believe that adding the new vaccine might help the immunotherapy work better by giving the immune system additional tools to fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. In Phase 1, a small group of patients will receive increasing doses of the new vaccine as injections (given without needles) in the arm and leg muscles, along with standard immunotherapy infusions. In Phase 2, a larger group will be randomly assigned to receive either the vaccine plus immunotherapy or immunotherapy alone. Treatment continues for up to 2 years or until your cancer stops responding, you experience unacceptable side effects, or you decide to withdraw. You will have regular visits for injections, infusions, blood tests, and scans to monitor how well the treatment is working.
AI-generated summary from trial data · Sep 3, 2026 · Not medical advice
France
Germany
Hungary
Norway